First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis
Three U.S. clinical trial sites actively screening and enrolling patients Top line data of adrulipase…
Three U.S. clinical trial sites actively screening and enrolling patients Top line data of adrulipase…
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader…
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader…
– Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined…
– Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined…
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage…
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage…
Montauk Brings Local Flavor to The K Korner at Citi Field with Fan-Favorite Montauk Brewing…
Montauk Brings Local Flavor to The K Korner at Citi Field with Fan-Favorite Montauk Brewing…
Virtual event on Tuesday, May 2, 2023 at 11:00am ET will feature key opinion leader…
Virtual event on Tuesday, May 2, 2023 at 11:00am ET will feature key opinion leader…
On track for initial readouts in Q2 2023 from ongoing Phase 1 VYD222 clinical trial…
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in…
On track for initial readouts in Q2 2023 from ongoing Phase 1 VYD222 clinical trial…
SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
-MORF-057 demonstrates statistically significant reduction of 6.4 points (p=0.002) from baseline at Week 12 in…
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and…
SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX…
-In EMERALD-1 Phase 2a trial in patients with ulcerative colitis, MORF-057 meets primary endpoint and…
SAWC Spring 2023 represents first clinical conference opportunity to introduce newly effective dedicated AC5 HCPCS…